CompletedNot Applicable

Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy

South Korea420 participantsStarted 2019-03-28

Plain-language summary

This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with pathologically confirmed pancreatic adenocarcinoma. Exclusion Criteria: * Patients disagree with the study.

What they're measuring

Clinical applicability of KRAS mutations

Timeframe: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months

Discovery of biomarkers through ctDNA panel

Timeframe: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months

Trial details

NCT IDNCT04241367

SponsorNational Cancer Center, Korea

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2021-06-03

View on ClinicalTrials.gov More Pancreas Adenocarcinoma trials